Sangamo Therapeutics, Inc. (SGMO) 10-Year Financial Performance & Capital Metrics

SGMO • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutSangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.Show more

Revenue $58M -67.2%
EBITDA -$95M +62.4%
Net Income -$98M +62.0%
EPS (Diluted) -0.49 +66.9%
Gross Margin 100%
EBITDA Margin -163.68% -14.6%
Operating Margin -179.88% -15.7%
Net Margin -169.45% -15.8%
ROE -185.39% -35.8%
ROIC -178.84% -36.4%
Debt/Equity 1.34 +192.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Weak momentum: RS Rating 19 (bottom 19%)
✗Sales declining 10.8% over 5 years
✗Shares diluted 15.6% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y2.34%

5Y-10.81%

3Y-19.48%

TTM-37.13%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM19.23%

EPS CAGR

10Y-

5Y-

3Y-

TTM41.33%

ROCE

10Y Avg-43.42%

5Y Avg-60.05%

3Y Avg-84.95%

Latest-119.91%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	39.54M	19.39M	36.57M	84.45M	102.43M	118.19M	110.7M	111.3M	176.23M	57.8M
Revenue Growth %	-0.14%	-0.51%	0.89%	1.31%	0.21%	0.15%	-0.06%	0.01%	0.58%	-0.67%
Cost of Goods Sold+	67.13M	65.62M	65.73M	114.87M	145.92M	180.65M	0	12.11M	0	0
COGS % of Revenue	1.7%	3.38%	1.8%	1.36%	1.42%	1.53%	-	0.11%	-	-
Gross Profit+	-27.59M	-46.23M	-29.16M	-30.41M	-43.49M	-62.45M	110.7M	99.19M	176.23M	57.8M
Gross Margin %	-0.7%	-2.38%	-0.8%	-0.36%	-0.42%	-0.53%	1%	0.89%	1%	1%
Gross Profit Growth %	-1.54%	-0.68%	0.37%	-0.04%	-0.43%	-0.44%	2.77%	-0.1%	0.78%	-0.67%
Operating Expenses+	86.39M	91.95M	92.93M	161.6M	61.69M	67.1M	294.04M	300.47M	450.24M	161.77M
OpEx % of Revenue	2.19%	4.74%	2.54%	1.91%	0.6%	0.57%	2.66%	2.7%	2.55%	2.8%
Selling, General & Admin	19.2M	26.33M	27.2M	46.74M	61.69M	67.1M	63.22M	62.68M	61.17M	44.73M
SG&A % of Revenue	0.49%	1.36%	0.74%	0.55%	0.6%	0.57%	0.57%	0.56%	0.35%	0.77%
Research & Development	67.2M	65.62M	65.73M	114.87M	145.92M	180.65M	230.82M	249.9M	234.06M	111.52M
R&D % of Revenue	1.7%	3.38%	1.8%	1.36%	1.42%	1.53%	2.09%	2.25%	1.33%	1.93%
Other Operating Expenses	431K	887K	0	0	-145.92M	-180.65M	0	-12.11M	155.01M	5.52M
Operating Income+	-46.86M	-72.56M	-56.36M	-77.15M	-105.18M	-129.55M	-183.34M	-201.28M	-274M	-103.97M
Operating Margin %	-1.19%	-3.74%	-1.54%	-0.91%	-1.03%	-1.1%	-1.66%	-1.81%	-1.55%	-1.8%
Operating Income Growth %	-0.75%	-0.55%	0.22%	-0.37%	-0.36%	-0.23%	-0.42%	-0.1%	-0.36%	0.62%
EBITDA+	-45.87M	-71.56M	-54.86M	-74.79M	-101.25M	-123.87M	-165.7M	-189.17M	-251.81M	-94.61M
EBITDA Margin %	-1.16%	-3.69%	-1.5%	-0.89%	-0.99%	-1.05%	-1.5%	-1.7%	-1.43%	-1.64%
EBITDA Growth %	-0.75%	-0.56%	0.23%	-0.36%	-0.35%	-0.22%	-0.34%	-0.14%	-0.33%	0.62%
D&A (Non-Cash Add-back)	988K	997K	1.5M	2.36M	3.93M	5.68M	17.64M	12.11M	22.19M	9.36M
EBIT	-46.86M	-71.67M	-56.36M	-77.15M	-105.18M	-129.55M	-183.34M	-201.28M	-118.99M	-98.45M
Net Interest Income+	431K	887K	1.79M	8.26M	9.76M	8.78M	5.35M	9.43M	11.1M	5.86M
Interest Income	431K	887K	1.79M	8.26M	9.76M	8.78M	5.35M	9.43M	11.1M	5.86M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	431K	887K	1.79M	8.26M	9.76M	8.77M	5.35M	9.43M	11.1M	5.86M
Pretax Income+	-46.42M	-71.67M	-54.57M	-68.89M	-95.42M	-120.78M	-177.99M	-191.85M	-262.9M	-98.11M
Pretax Margin %	-1.17%	-3.7%	-1.49%	-0.82%	-0.93%	-1.02%	-1.61%	-1.72%	-1.49%	-1.7%
Income Tax+	-5.72M	-14K	0	0	0	345K	306K	429K	-5.07M	-167K
Effective Tax Rate %	0.88%	1%	1%	0.99%	1%	1%	1%	1%	0.98%	1%
Net Income+	-40.7M	-71.66M	-54.57M	-68.33M	-95.19M	-121M	-178.29M	-192.28M	-257.83M	-97.94M
Net Margin %	-1.03%	-3.7%	-1.49%	-0.81%	-0.93%	-1.02%	-1.61%	-1.73%	-1.46%	-1.69%
Net Income Growth %	-0.54%	-0.76%	0.24%	-0.25%	-0.39%	-0.27%	-0.47%	-0.08%	-0.34%	0.62%
Net Income (Continuing)	-40.7M	-71.66M	-54.57M	-68.89M	-95.42M	-121.12M	-178.3M	-192.28M	-257.83M	-97.94M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	739K	185K	-868K	0	0	0	0
EPS (Diluted)+	-0.58	-1.02	-0.70	-0.70	-0.68	-0.90	-1.23	-1.25	-1.48	-0.49
EPS Growth %	-0.49%	-0.76%	0.31%	0%	0.03%	-0.32%	-0.37%	-0.02%	-0.18%	0.67%
EPS (Basic)	-0.58	-1.02	-0.70	-0.70	-0.68	-0.90	-1.23	-1.25	-1.48	-0.49
Diluted Shares Outstanding	69.76M	70.55M	78.08M	96.94M	112.11M	134.45M	144.57M	154.34M	174.44M	201.7M
Basic Shares Outstanding	69.76M	70.55M	78.08M	96.94M	112.11M	134.45M	144.57M	154.34M	174.44M	201.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	212.58M	149.58M	248.4M	410.52M	405.47M	659.67M	398.77M	300.33M	94.33M	51.69M
Cash & Short-Term Investments	209.31M	142.76M	244.56M	400.51M	362.47M	641.42M	376.55M	277.63M	81M	41.92M
Cash Only	69.48M	22.06M	49.83M	140.42M	80.43M	131.33M	178.87M	100.44M	45.2M	41.92M
Short-Term Investments	139.52M	120.47M	193.48M	259.71M	282.05M	510.09M	197.68M	177.19M	35.8M	0
Accounts Receivable	2.83M	5.2M	3.58M	5.05M	37.59M	6.26M	6.36M	4.47M	4.07M	4.6M
Days Sales Outstanding	26.11	97.82	35.76	21.82	133.95	19.33	20.98	14.67	8.42	29.04
Inventory	-307K	-224K	-1.25M	-375K	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	1.51M	5.34M	0	0	0	0	9.26M	5.17M
Total Non-Current Assets+	4.65M	8.31M	38.34M	179.87M	232.04M	278.88M	323.15M	262.18M	70.99M	49.94M
Property, Plant & Equipment	2.92M	6.56M	31.07M	78.72M	107.22M	112.37M	124.7M	125.53M	52.87M	34.76M
Fixed Asset Turnover	13.56x	2.96x	1.18x	1.07x	0.96x	1.05x	0.89x	0.89x	3.33x	1.66x
Goodwill	1.58M	1.58M	1.58M	40.04M	39.27M	42.8M	39.7M	37.55M	0	0
Intangible Assets	0	0	0	54.87M	53.16M	58.13M	53.76M	50.73M	0	0
Long-Term Investments	0	0	1.01M	-6.71M	21.83M	50.53M	88.17M	29.84M	1.5M	1.5M
Other Non-Current Assets	152K	169K	4.68M	6.24M	10.57M	15.06M	16.82M	12.25M	16.63M	13.69M
Total Assets+	217.24M	157.89M	286.74M	590.39M	637.52M	938.55M	721.92M	562.51M	165.32M	101.64M
Asset Turnover	0.18x	0.12x	0.13x	0.14x	0.16x	0.13x	0.15x	0.20x	1.07x	0.57x
Asset Growth %	-0.11%	-0.27%	0.82%	1.06%	0.08%	0.47%	-0.23%	-0.22%	-0.71%	-0.39%
Total Current Liabilities+	20.1M	13.29M	44.86M	78.51M	69.87M	143.55M	127.89M	111.71M	47.73M	45.8M
Accounts Payable	3.9M	2.58M	16K	3.35M	6.67M	12.55M	9.76M	22.42M	15.26M	15.48M
Days Payables Outstanding	21.23	14.35	0.09	10.66	16.69	25.36	-	675.8	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0	1000K
Other Current Liabilities	2.94M	3.38M	5.9M	9.69M	13.61M	20.74M	20.84M	11.88M	11.73M	14.57M
Current Ratio	10.58x	11.25x	5.54x	5.23x	5.80x	4.60x	3.12x	2.69x	1.98x	1.13x
Quick Ratio	10.59x	11.27x	5.57x	5.23x	5.80x	4.60x	3.12x	2.69x	1.98x	1.13x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	4.7M	8.4M	53.98M	144.63M	134.91M	297.64M	218.69M	155.84M	34.7M	33.06M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	3.94M	24.74M	27.69M	41.19M	38.4M	44.05M	38.99M	33.52M	26.25M
Deferred Tax Liabilities	0	-3.94M	-24.74M	6.71M	6.57M	7.18M	6.64M	6.27M	0	0
Other Non-Current Liabilities	0	0	0	1.96M	5.71M	7.01M	1.22M	1.21M	1.19M	933K
Total Liabilities	24.8M	21.7M	98.84M	223.88M	204.78M	441.18M	346.58M	267.55M	82.43M	78.86M
Total Debt+	0	3.94M	24.74M	27.69M	44.41M	42.09M	48.08M	43.11M	38.1M	30.57M
Net Debt	-69.48M	-18.12M	-25.09M	-112.73M	-36.02M	-89.24M	-130.79M	-57.34M	-7.1M	-11.35M
Debt / Equity	-	0.03x	0.13x	0.08x	0.10x	0.08x	0.13x	0.15x	0.46x	1.34x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	192.44M	136.19M	187.9M	367.26M	432.74M	497.37M	375.34M	294.96M	82.89M	22.77M
Equity Growth %	-0.07%	-0.29%	0.38%	0.95%	0.18%	0.15%	-0.25%	-0.21%	-0.72%	-0.73%
Book Value per Share	2.76	1.93	2.41	3.79	3.86	3.70	2.60	1.91	0.48	0.11
Total Shareholders' Equity	192.44M	136.19M	187.9M	366.52M	432.55M	498.23M	375.34M	294.96M	82.89M	22.77M
Common Stock	703K	709K	856K	1.02M	1.16M	1.42M	1.46M	1.67M	1.78M	2.13M
Retained Earnings	-369.25M	-440.91M	-495.48M	-562.7M	-656.99M	-777.98M	-956.27M	-1.15B	-1.41B	-1.5B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-4.85M	20K	-286K	-1.44M	-2.45M	5.42M	-3.99M	-8.4M	-4.59M	-7.53M
Minority Interest	0	0	0	739K	185K	-868K	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-33.72M	-65.88M	11.18M	37.15M	-144.4M	169.88M	-233.25M	-223.63M	-224.84M	-67.14M
Operating CF Margin %	-0.85%	-3.4%	0.31%	0.44%	-1.41%	1.44%	-2.11%	-2.01%	-1.28%	-1.16%
Operating CF Growth %	-4.94%	-0.95%	1.17%	2.32%	-4.89%	2.18%	-2.37%	0.04%	-0.01%	0.7%
Net Income	-40.7M	-71.66M	-54.57M	-68.89M	-95.42M	-121.12M	-178.3M	-192.28M	-257.83M	-97.94M
Depreciation & Amortization	988K	997K	1.5M	2.36M	9.61M	13.37M	17.64M	20.56M	22.19M	9.36M
Stock-Based Compensation	11.73M	15.06M	9.09M	14.68M	19.33M	25.71M	32.96M	31.65M	27.36M	12.38M
Deferred Taxes	-5.72M	-14K	-661K	-5.23M	-5.13M	0	2.77M	0	-6.33M	0
Other Non-Cash Items	897K	320K	80K	966K	218K	-666K	-6.43M	-1.24M	153.8M	4.55M
Working Capital Changes	-910K	-10.59M	55.74M	93.27M	-73.01M	252.59M	-101.89M	-82.32M	-164.03M	4.51M
Change in Receivables	7.85M	-2.14M	1.63M	-1.33M	-32.24M	31.68M	-789K	2.33M	-976K	953K
Change in Inventory	492K	-1.03M	-685K	-1M	4.19M	-10.7M	7.66M	0	0	0
Change in Payables	-764K	-2.33M	3.22M	-6.37M	-4.19M	10.7M	-7.66M	13.35M	5.59M	-14.17M
Cash from Investing+	77.46M	18.13M	-80.9M	-178.11M	-59.8M	-271.63M	248.2M	59.28M	153.53M	37.52M
Capital Expenditures	-2.41M	-732K	-3.75M	-43.06M	-20.68M	-14.71M	-23.28M	-20.17M	-21.16M	-267K
CapEx % of Revenue	0.06%	0.04%	0.1%	0.51%	0.2%	0.12%	0.21%	0.18%	0.12%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	2M	18.86M	-3.5M	-59.39M	0	0	0	79.46M	0	0
Cash from Financing+	19.71M	337K	97.49M	231.71M	142.03M	153.1M	32.86M	84.66M	14.59M	28.38M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	12.91M	-776K	15.92M	15.95M	5.72M	10.57M	5.76M	-209K	-518K	-614K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-36.13M	-66.61M	7.43M	-5.91M	-165.08M	155.16M	-256.53M	-243.8M	-246M	-67.41M
FCF Margin %	-0.91%	-3.44%	0.2%	-0.07%	-1.61%	1.31%	-2.32%	-2.19%	-1.4%	-1.17%
FCF Growth %	-4.74%	-0.84%	1.11%	-1.8%	-26.92%	1.94%	-2.65%	0.05%	-0.01%	0.73%
FCF per Share	-0.52	-0.94	0.10	-0.06	-1.47	1.15	-1.77	-1.58	-1.41	-0.33
FCF Conversion (FCF/Net Income)	0.83x	0.92x	-0.20x	-0.54x	1.52x	-1.40x	1.31x	1.16x	0.87x	0.69x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-20.4%	-43.61%	-33.67%	-24.62%	-23.8%	-26.02%	-40.86%	-57.37%	-136.47%	-185.39%
Return on Invested Capital (ROIC)	-21.72%	-45.15%	-30.1%	-27.73%	-24.23%	-24.14%	-42.14%	-62.62%	-131.14%	-178.84%
Gross Margin	-69.78%	-238.43%	-79.75%	-36.01%	-42.46%	-52.84%	100%	89.12%	100%	100%
Net Margin	-102.94%	-369.58%	-149.23%	-80.91%	-92.93%	-102.37%	-161.05%	-172.76%	-146.3%	-169.45%
Debt / Equity	-	0.03x	0.13x	0.08x	0.10x	0.08x	0.13x	0.15x	0.46x	1.34x
FCF Conversion	0.83x	0.92x	-0.20x	-0.54x	1.52x	-1.40x	1.31x	1.16x	0.87x	0.69x
Revenue Growth	-13.8%	-50.96%	88.6%	130.95%	21.29%	15.39%	-6.34%	0.54%	58.34%	-67.2%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
License	-	-	-	-	37.03M	132.16M	48.68M
License Growth	-	-	-	-	-	256.89%	-63.17%
Service	-	-	-	-	-	2.68M	1.32M
Service Growth	-	-	-	-	-	-	-50.78%
License and Service	-	3.49M	298K	34K	19.7M	9.57M	-
License and Service Growth	-	-	-91.47%	-88.59%	57841.18%	-51.43%	-
Research Services	9.5M	6.37M	4.82M	3.06M	2.13M	-	-
Research Services Growth	-	-33.00%	-24.25%	-36.62%	-30.45%	-	-
Milestone Achievement	-	12.82M	201K	23K	457K	-	-
Milestone Achievement Growth	-	-	-98.43%	-88.56%	1886.96%	-	-
License And Service	37.8M	-	-	-	-	-	-
License And Service Growth	-	-	-	-	-	-	-
C Nine O R F Seven Two	2.2M	-	-	-	-	-	-
C Nine O R F Seven Two Growth	-	-	-	-	-	-	-
Royalty	-	-	-	-	-	-	-
Royalty Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Sangamo Therapeutics, Inc. (SGMO) reported $32.9M in revenue for fiscal year 2024. This represents a 219% increase from $10.3M in 2011.

Sangamo Therapeutics, Inc. (SGMO) saw revenue decline by 67.2% over the past year.

Sangamo Therapeutics, Inc. (SGMO) reported a net loss of $108.9M for fiscal year 2024.

Dividend & Returns

Sangamo Therapeutics, Inc. (SGMO) has a return on equity (ROE) of -185.4%. Negative ROE indicates the company is unprofitable.

Sangamo Therapeutics, Inc. (SGMO) had negative free cash flow of $76.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Sangamo Therapeutics, Inc. (SGMO) 10-Year Financial Performance & Capital Metrics

SGMO • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $58M -67.2%
EBITDA -$95M +62.4%
Net Income -$98M +62.0%
EPS (Diluted) -0.49 +66.9%
Gross Margin 100%
EBITDA Margin -163.68% -14.6%
Operating Margin -179.88% -15.7%
Net Margin -169.45% -15.8%
ROE -185.39% -35.8%
ROIC -178.84% -36.4%
Debt/Equity 1.34 +192.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Weak momentum: RS Rating 19 (bottom 19%)
✗Sales declining 10.8% over 5 years
✗Shares diluted 15.6% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y2.34%

5Y-10.81%

3Y-19.48%

TTM-37.13%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM19.23%

EPS CAGR

10Y-

5Y-

3Y-

TTM41.33%

ROCE

10Y Avg-43.42%

5Y Avg-60.05%

3Y Avg-84.95%

Latest-119.91%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	39.54M	19.39M	36.57M	84.45M	102.43M	118.19M	110.7M	111.3M	176.23M	57.8M
Revenue Growth %	-0.14%	-0.51%	0.89%	1.31%	0.21%	0.15%	-0.06%	0.01%	0.58%	-0.67%
Cost of Goods Sold+	67.13M	65.62M	65.73M	114.87M	145.92M	180.65M	0	12.11M	0	0
COGS % of Revenue	1.7%	3.38%	1.8%	1.36%	1.42%	1.53%	-	0.11%	-	-
Gross Profit+	-27.59M	-46.23M	-29.16M	-30.41M	-43.49M	-62.45M	110.7M	99.19M	176.23M	57.8M
Gross Margin %	-0.7%	-2.38%	-0.8%	-0.36%	-0.42%	-0.53%	1%	0.89%	1%	1%
Gross Profit Growth %	-1.54%	-0.68%	0.37%	-0.04%	-0.43%	-0.44%	2.77%	-0.1%	0.78%	-0.67%
Operating Expenses+	86.39M	91.95M	92.93M	161.6M	61.69M	67.1M	294.04M	300.47M	450.24M	161.77M
OpEx % of Revenue	2.19%	4.74%	2.54%	1.91%	0.6%	0.57%	2.66%	2.7%	2.55%	2.8%
Selling, General & Admin	19.2M	26.33M	27.2M	46.74M	61.69M	67.1M	63.22M	62.68M	61.17M	44.73M
SG&A % of Revenue	0.49%	1.36%	0.74%	0.55%	0.6%	0.57%	0.57%	0.56%	0.35%	0.77%
Research & Development	67.2M	65.62M	65.73M	114.87M	145.92M	180.65M	230.82M	249.9M	234.06M	111.52M
R&D % of Revenue	1.7%	3.38%	1.8%	1.36%	1.42%	1.53%	2.09%	2.25%	1.33%	1.93%
Other Operating Expenses	431K	887K	0	0	-145.92M	-180.65M	0	-12.11M	155.01M	5.52M
Operating Income+	-46.86M	-72.56M	-56.36M	-77.15M	-105.18M	-129.55M	-183.34M	-201.28M	-274M	-103.97M
Operating Margin %	-1.19%	-3.74%	-1.54%	-0.91%	-1.03%	-1.1%	-1.66%	-1.81%	-1.55%	-1.8%
Operating Income Growth %	-0.75%	-0.55%	0.22%	-0.37%	-0.36%	-0.23%	-0.42%	-0.1%	-0.36%	0.62%
EBITDA+	-45.87M	-71.56M	-54.86M	-74.79M	-101.25M	-123.87M	-165.7M	-189.17M	-251.81M	-94.61M
EBITDA Margin %	-1.16%	-3.69%	-1.5%	-0.89%	-0.99%	-1.05%	-1.5%	-1.7%	-1.43%	-1.64%
EBITDA Growth %	-0.75%	-0.56%	0.23%	-0.36%	-0.35%	-0.22%	-0.34%	-0.14%	-0.33%	0.62%
D&A (Non-Cash Add-back)	988K	997K	1.5M	2.36M	3.93M	5.68M	17.64M	12.11M	22.19M	9.36M
EBIT	-46.86M	-71.67M	-56.36M	-77.15M	-105.18M	-129.55M	-183.34M	-201.28M	-118.99M	-98.45M
Net Interest Income+	431K	887K	1.79M	8.26M	9.76M	8.78M	5.35M	9.43M	11.1M	5.86M
Interest Income	431K	887K	1.79M	8.26M	9.76M	8.78M	5.35M	9.43M	11.1M	5.86M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	431K	887K	1.79M	8.26M	9.76M	8.77M	5.35M	9.43M	11.1M	5.86M
Pretax Income+	-46.42M	-71.67M	-54.57M	-68.89M	-95.42M	-120.78M	-177.99M	-191.85M	-262.9M	-98.11M
Pretax Margin %	-1.17%	-3.7%	-1.49%	-0.82%	-0.93%	-1.02%	-1.61%	-1.72%	-1.49%	-1.7%
Income Tax+	-5.72M	-14K	0	0	0	345K	306K	429K	-5.07M	-167K
Effective Tax Rate %	0.88%	1%	1%	0.99%	1%	1%	1%	1%	0.98%	1%
Net Income+	-40.7M	-71.66M	-54.57M	-68.33M	-95.19M	-121M	-178.29M	-192.28M	-257.83M	-97.94M
Net Margin %	-1.03%	-3.7%	-1.49%	-0.81%	-0.93%	-1.02%	-1.61%	-1.73%	-1.46%	-1.69%
Net Income Growth %	-0.54%	-0.76%	0.24%	-0.25%	-0.39%	-0.27%	-0.47%	-0.08%	-0.34%	0.62%
Net Income (Continuing)	-40.7M	-71.66M	-54.57M	-68.89M	-95.42M	-121.12M	-178.3M	-192.28M	-257.83M	-97.94M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	739K	185K	-868K	0	0	0	0
EPS (Diluted)+	-0.58	-1.02	-0.70	-0.70	-0.68	-0.90	-1.23	-1.25	-1.48	-0.49
EPS Growth %	-0.49%	-0.76%	0.31%	0%	0.03%	-0.32%	-0.37%	-0.02%	-0.18%	0.67%
EPS (Basic)	-0.58	-1.02	-0.70	-0.70	-0.68	-0.90	-1.23	-1.25	-1.48	-0.49
Diluted Shares Outstanding	69.76M	70.55M	78.08M	96.94M	112.11M	134.45M	144.57M	154.34M	174.44M	201.7M
Basic Shares Outstanding	69.76M	70.55M	78.08M	96.94M	112.11M	134.45M	144.57M	154.34M	174.44M	201.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	212.58M	149.58M	248.4M	410.52M	405.47M	659.67M	398.77M	300.33M	94.33M	51.69M
Cash & Short-Term Investments	209.31M	142.76M	244.56M	400.51M	362.47M	641.42M	376.55M	277.63M	81M	41.92M
Cash Only	69.48M	22.06M	49.83M	140.42M	80.43M	131.33M	178.87M	100.44M	45.2M	41.92M
Short-Term Investments	139.52M	120.47M	193.48M	259.71M	282.05M	510.09M	197.68M	177.19M	35.8M	0
Accounts Receivable	2.83M	5.2M	3.58M	5.05M	37.59M	6.26M	6.36M	4.47M	4.07M	4.6M
Days Sales Outstanding	26.11	97.82	35.76	21.82	133.95	19.33	20.98	14.67	8.42	29.04
Inventory	-307K	-224K	-1.25M	-375K	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	1.51M	5.34M	0	0	0	0	9.26M	5.17M
Total Non-Current Assets+	4.65M	8.31M	38.34M	179.87M	232.04M	278.88M	323.15M	262.18M	70.99M	49.94M
Property, Plant & Equipment	2.92M	6.56M	31.07M	78.72M	107.22M	112.37M	124.7M	125.53M	52.87M	34.76M
Fixed Asset Turnover	13.56x	2.96x	1.18x	1.07x	0.96x	1.05x	0.89x	0.89x	3.33x	1.66x
Goodwill	1.58M	1.58M	1.58M	40.04M	39.27M	42.8M	39.7M	37.55M	0	0
Intangible Assets	0	0	0	54.87M	53.16M	58.13M	53.76M	50.73M	0	0
Long-Term Investments	0	0	1.01M	-6.71M	21.83M	50.53M	88.17M	29.84M	1.5M	1.5M
Other Non-Current Assets	152K	169K	4.68M	6.24M	10.57M	15.06M	16.82M	12.25M	16.63M	13.69M
Total Assets+	217.24M	157.89M	286.74M	590.39M	637.52M	938.55M	721.92M	562.51M	165.32M	101.64M
Asset Turnover	0.18x	0.12x	0.13x	0.14x	0.16x	0.13x	0.15x	0.20x	1.07x	0.57x
Asset Growth %	-0.11%	-0.27%	0.82%	1.06%	0.08%	0.47%	-0.23%	-0.22%	-0.71%	-0.39%
Total Current Liabilities+	20.1M	13.29M	44.86M	78.51M	69.87M	143.55M	127.89M	111.71M	47.73M	45.8M
Accounts Payable	3.9M	2.58M	16K	3.35M	6.67M	12.55M	9.76M	22.42M	15.26M	15.48M
Days Payables Outstanding	21.23	14.35	0.09	10.66	16.69	25.36	-	675.8	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0	1000K
Other Current Liabilities	2.94M	3.38M	5.9M	9.69M	13.61M	20.74M	20.84M	11.88M	11.73M	14.57M
Current Ratio	10.58x	11.25x	5.54x	5.23x	5.80x	4.60x	3.12x	2.69x	1.98x	1.13x
Quick Ratio	10.59x	11.27x	5.57x	5.23x	5.80x	4.60x	3.12x	2.69x	1.98x	1.13x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	4.7M	8.4M	53.98M	144.63M	134.91M	297.64M	218.69M	155.84M	34.7M	33.06M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	3.94M	24.74M	27.69M	41.19M	38.4M	44.05M	38.99M	33.52M	26.25M
Deferred Tax Liabilities	0	-3.94M	-24.74M	6.71M	6.57M	7.18M	6.64M	6.27M	0	0
Other Non-Current Liabilities	0	0	0	1.96M	5.71M	7.01M	1.22M	1.21M	1.19M	933K
Total Liabilities	24.8M	21.7M	98.84M	223.88M	204.78M	441.18M	346.58M	267.55M	82.43M	78.86M
Total Debt+	0	3.94M	24.74M	27.69M	44.41M	42.09M	48.08M	43.11M	38.1M	30.57M
Net Debt	-69.48M	-18.12M	-25.09M	-112.73M	-36.02M	-89.24M	-130.79M	-57.34M	-7.1M	-11.35M
Debt / Equity	-	0.03x	0.13x	0.08x	0.10x	0.08x	0.13x	0.15x	0.46x	1.34x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	192.44M	136.19M	187.9M	367.26M	432.74M	497.37M	375.34M	294.96M	82.89M	22.77M
Equity Growth %	-0.07%	-0.29%	0.38%	0.95%	0.18%	0.15%	-0.25%	-0.21%	-0.72%	-0.73%
Book Value per Share	2.76	1.93	2.41	3.79	3.86	3.70	2.60	1.91	0.48	0.11
Total Shareholders' Equity	192.44M	136.19M	187.9M	366.52M	432.55M	498.23M	375.34M	294.96M	82.89M	22.77M
Common Stock	703K	709K	856K	1.02M	1.16M	1.42M	1.46M	1.67M	1.78M	2.13M
Retained Earnings	-369.25M	-440.91M	-495.48M	-562.7M	-656.99M	-777.98M	-956.27M	-1.15B	-1.41B	-1.5B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-4.85M	20K	-286K	-1.44M	-2.45M	5.42M	-3.99M	-8.4M	-4.59M	-7.53M
Minority Interest	0	0	0	739K	185K	-868K	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-33.72M	-65.88M	11.18M	37.15M	-144.4M	169.88M	-233.25M	-223.63M	-224.84M	-67.14M
Operating CF Margin %	-0.85%	-3.4%	0.31%	0.44%	-1.41%	1.44%	-2.11%	-2.01%	-1.28%	-1.16%
Operating CF Growth %	-4.94%	-0.95%	1.17%	2.32%	-4.89%	2.18%	-2.37%	0.04%	-0.01%	0.7%
Net Income	-40.7M	-71.66M	-54.57M	-68.89M	-95.42M	-121.12M	-178.3M	-192.28M	-257.83M	-97.94M
Depreciation & Amortization	988K	997K	1.5M	2.36M	9.61M	13.37M	17.64M	20.56M	22.19M	9.36M
Stock-Based Compensation	11.73M	15.06M	9.09M	14.68M	19.33M	25.71M	32.96M	31.65M	27.36M	12.38M
Deferred Taxes	-5.72M	-14K	-661K	-5.23M	-5.13M	0	2.77M	0	-6.33M	0
Other Non-Cash Items	897K	320K	80K	966K	218K	-666K	-6.43M	-1.24M	153.8M	4.55M
Working Capital Changes	-910K	-10.59M	55.74M	93.27M	-73.01M	252.59M	-101.89M	-82.32M	-164.03M	4.51M
Change in Receivables	7.85M	-2.14M	1.63M	-1.33M	-32.24M	31.68M	-789K	2.33M	-976K	953K
Change in Inventory	492K	-1.03M	-685K	-1M	4.19M	-10.7M	7.66M	0	0	0
Change in Payables	-764K	-2.33M	3.22M	-6.37M	-4.19M	10.7M	-7.66M	13.35M	5.59M	-14.17M
Cash from Investing+	77.46M	18.13M	-80.9M	-178.11M	-59.8M	-271.63M	248.2M	59.28M	153.53M	37.52M
Capital Expenditures	-2.41M	-732K	-3.75M	-43.06M	-20.68M	-14.71M	-23.28M	-20.17M	-21.16M	-267K
CapEx % of Revenue	0.06%	0.04%	0.1%	0.51%	0.2%	0.12%	0.21%	0.18%	0.12%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	2M	18.86M	-3.5M	-59.39M	0	0	0	79.46M	0	0
Cash from Financing+	19.71M	337K	97.49M	231.71M	142.03M	153.1M	32.86M	84.66M	14.59M	28.38M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	12.91M	-776K	15.92M	15.95M	5.72M	10.57M	5.76M	-209K	-518K	-614K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-36.13M	-66.61M	7.43M	-5.91M	-165.08M	155.16M	-256.53M	-243.8M	-246M	-67.41M
FCF Margin %	-0.91%	-3.44%	0.2%	-0.07%	-1.61%	1.31%	-2.32%	-2.19%	-1.4%	-1.17%
FCF Growth %	-4.74%	-0.84%	1.11%	-1.8%	-26.92%	1.94%	-2.65%	0.05%	-0.01%	0.73%
FCF per Share	-0.52	-0.94	0.10	-0.06	-1.47	1.15	-1.77	-1.58	-1.41	-0.33
FCF Conversion (FCF/Net Income)	0.83x	0.92x	-0.20x	-0.54x	1.52x	-1.40x	1.31x	1.16x	0.87x	0.69x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-20.4%	-43.61%	-33.67%	-24.62%	-23.8%	-26.02%	-40.86%	-57.37%	-136.47%	-185.39%
Return on Invested Capital (ROIC)	-21.72%	-45.15%	-30.1%	-27.73%	-24.23%	-24.14%	-42.14%	-62.62%	-131.14%	-178.84%
Gross Margin	-69.78%	-238.43%	-79.75%	-36.01%	-42.46%	-52.84%	100%	89.12%	100%	100%
Net Margin	-102.94%	-369.58%	-149.23%	-80.91%	-92.93%	-102.37%	-161.05%	-172.76%	-146.3%	-169.45%
Debt / Equity	-	0.03x	0.13x	0.08x	0.10x	0.08x	0.13x	0.15x	0.46x	1.34x
FCF Conversion	0.83x	0.92x	-0.20x	-0.54x	1.52x	-1.40x	1.31x	1.16x	0.87x	0.69x
Revenue Growth	-13.8%	-50.96%	88.6%	130.95%	21.29%	15.39%	-6.34%	0.54%	58.34%	-67.2%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
License	-	-	-	-	37.03M	132.16M	48.68M
License Growth	-	-	-	-	-	256.89%	-63.17%
Service	-	-	-	-	-	2.68M	1.32M
Service Growth	-	-	-	-	-	-	-50.78%
License and Service	-	3.49M	298K	34K	19.7M	9.57M	-
License and Service Growth	-	-	-91.47%	-88.59%	57841.18%	-51.43%	-
Research Services	9.5M	6.37M	4.82M	3.06M	2.13M	-	-
Research Services Growth	-	-33.00%	-24.25%	-36.62%	-30.45%	-	-
Milestone Achievement	-	12.82M	201K	23K	457K	-	-
Milestone Achievement Growth	-	-	-98.43%	-88.56%	1886.96%	-	-
License And Service	37.8M	-	-	-	-	-	-
License And Service Growth	-	-	-	-	-	-	-
C Nine O R F Seven Two	2.2M	-	-	-	-	-	-
C Nine O R F Seven Two Growth	-	-	-	-	-	-	-
Royalty	-	-	-	-	-	-	-
Royalty Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Sangamo Therapeutics, Inc. (SGMO) reported $32.9M in revenue for fiscal year 2024. This represents a 219% increase from $10.3M in 2011.

Sangamo Therapeutics, Inc. (SGMO) saw revenue decline by 67.2% over the past year.

Sangamo Therapeutics, Inc. (SGMO) reported a net loss of $108.9M for fiscal year 2024.

Dividend & Returns

Sangamo Therapeutics, Inc. (SGMO) has a return on equity (ROE) of -185.4%. Negative ROE indicates the company is unprofitable.

Sangamo Therapeutics, Inc. (SGMO) had negative free cash flow of $76.4M in fiscal year 2024, likely due to heavy capital investments.